title: [Use of erbisol in chronic pancreatitis, depending on treatment options and concurrent ischemic heart disease in old and senile persons].
abstract: In old and senile persons, chronic pancreatitis is known to be accompanied by an uncontrolled intensification of process of free-radical lipid oxidation and inhibition of mechanisms of antiradical defence. The use of erbisol in the instituted therapeutic complex has been found to raise the efficiency of the system of glutathione and glutathione-dependent enzymes, to effect the inhibition of process of free-radical oxidation, improvement of conditions under which the synthesis of reduced glutathione is normally seen to proceed, realization of antiperoxide, disulphide reductase- and ribonucleotide reductase functions of the system as a whole. Moreover, there gets improved the incretory and exacrinous functions of the pancreas.
authors.forename: T N
authors.initials: TN
authors.lastname: Khristich
authors.forename: A N
authors.initials: AN
authors.lastname: Nikolaenko
authors.forename: T B
authors.initials: TB
authors.lastname: Kendzerskaia
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000544:Alzheimer Disease / Q000150:complications; D001685:Biological Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications*; D010195:Pancreatitis / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D001685:Biological Factors; C096287:erbisol